Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled TrialAviv Pudipeddi, Rupert W. Leong, Mark G. Ward et al.|Clinical Gastroenterology and Hepatology|2024Cited by 17
1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Sudarshan Paramsothy et al.|Gastroenterology|2023Cited by 2
P0257 Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trialAviv Pudipeddi, Rupert W. Leong, P Dhanji et al.|Journal of Crohn s and Colitis|2025Cited by 0
Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Sudarshan Paramsothy et al.|Gastroenterology|2025Cited by 0
Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIALAviv Pudipeddi, Rupert W. Leong, Sudarshan Paramsothy et al.|Gastroenterology|2025Cited by 0